...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Medical and Paediatric Oncology >Primary diffuse large B-cell lymphoma of the breast: Treatment and long-term outcome of two cases
【24h】

Primary diffuse large B-cell lymphoma of the breast: Treatment and long-term outcome of two cases

机译：主要弥漫性大型B细胞乳腺淋巴瘤：治疗和两种情况的长期结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Primary breast lymphoma (PBL) is a rare form of extranodal non-Hodgkin's lymphoma (NHL). It accounts for 0.5% of all breast malignancies and 2% extranodal NHL. Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype. We report three cases of PBL diagnosed and treated at our center. The clinical records of three female patients diagnosed with PBL from 2004 to 2015 were reviewed. Two patients had DLBCL, and the third patient had anaplastic large cell (ALCL) NHL. The mean age at presentation was 56 years. One patient with DLBCL was treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy and the second patient with rituximab plus CHOP chemotherapy. Both the patients showed complete response and have had a disease-free survival of 84 and 96 months, respectively. The third patient with ALCL refused further treatment after confirmation of diagnosis. PBL-DLBCL can be successful treated with chemotherapy, and long-term survival is similar to nodal NHL.
机译：原发性乳腺淋巴瘤（PBL）是一种罕见的外骨非霍奇金淋巴瘤（NHL）。它占所有乳腺恶性肿瘤的<0.5％和2％的外胚NHL。弥漫性大B细胞淋巴瘤（DLBCL）是最常见的组织学亚型。我们报告了在我们中心诊断和治疗的PBL患者。综述了诊断患有PBL 2004年至2015年PBL的三位女性患者的临床记录。两名患者有DLBCL，第三患者具有共产性大细胞（ALCL）NHL。介绍的平均年龄为56岁。用环磷酰胺，多柔比蛋白，长春酮和泼尼松龙（Chec）化疗和Rituximab和Cho Chemothapy的第二患者处理了一种患者。患者均表现出完全反应，分别具有84和96个月的无病生存率。在确认诊断后，第三名患者拒绝进一步治疗。 PBL-DLBCL可以用化疗成功治疗，长期存活类似于节点NHL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号